Interaction of Statins with Grapefruit Juice

Grapefruit juice, which discovered to interact with felodipine for the first time, is now known to interact with more that 80 drugs. Statins are among the drugs that interact with grapefruit juice. Grapefruit juice-statin interactions were first investigated in 1998 in human pharmacokinetic studies with lovastatin and simvastatin. The pharmacokinetic and pharmacodynamic basis of the interaction has been extensively investigated in studies. Flavonoids and furanocoumarins, the main components of grapefruit juice, have been reported to cause drug interactions. Furthermore, statin-grapefruit juice interactions occur mostly through inhibition of cytochrome-3A4 (CYP3A4), to a lesser extent through inhibition of P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs). Changes in plasma drug levels as a result of interaction may increase the side-effect of statins or reduce their therapeutic efficacy. Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.

Keywords:

Grapefruit juice, drug interaction, statins, CYP3A4 P-gp, OATP,

PDF

___

Amly, W., Karaman, R. (2015). Commonly used drugs uses, side effects, bioavailability and approaches to improve it. 1th ed. Nova Science Publishers, USA, 131-172.
Ando, H., Tsuruoka, S., Yanagihara, H., Sugimoto, K.I., Miyata, M., Yamazoe, Y., Takamura, T., Kaneko, S., Fujimura, A. (2005). Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. British Journal of Clinical Pharmacology, 60(5), 494-497. doi: 10.1111/j.1365-2125.2005.02462.x.
Bailey, D.G., Spence, J.D., Edgar, B., Bayliff, C.D., Arnold, J.M. (1989). Ethanol enhances the hemodynamic effects of felodipine. Clinical and Investigative Medicine, 12(6), 357-362.
Bailey, D.G., Kreeft, J.H., Munoz, C., Freeman, D.J., Bend, J.R. (1998). Grapefruit juice-felodipine interaction: Effect of naringin and 6’,7’-dihydroxybergamottin in humans. Clinical Pharmacology & Therapeutics, 64(3), 248-256. doi: https://doi.org/10.1016/S0009-9236(98)90173-4.
Bailey, D.G., Dresser, G.K. (2004). Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs, 4(5), 281-297. doi: https://doi.org/10.2165/00129784-200404050-00002.
Bailey, D.G. (2010). Fruit juice inhibition of uptake transport: a new type of food–drug interaction. British Journal of Clinical Pharmacology, 70(5), 645-655. doi: 10.1111/j.1365-2125.2010.03722.x
Bailey, D.G., Dresser, G., Arnold, M.O. (2013). Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? Canadian Medical Association Journal, 185(4), 309-316. doi: https://doi.org/10.1503/cmaj.120951.
Bang, L.M., Goa, K.L. (2003). Pravastatin a review of its use in elderly patients. Drugs Aging, 20(14), 1061-1082. doi: https://doi.org/10.2165/00002512-200320140-00005.
Bellosta, S., Paoletti, R., Corsini, A. (2004). Safety of statins focus on clinical pharmacokinetics and drug Interactions. Circulation, 109(23), 50-57. doi: 10.1161/01.CIR.0000131519.15067.1f.
Bonsu, K.O., Kadirvelu, A., Reidpath, D.D. (2013). Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Systematic Reviews, 2(22), 1-7. doi: 10.1186/2046-4053-2-22.
Carella, A.M., Marinelli, T., Melfitano, A., Di Pumpo, M., Conte, M., Modola, G., Puntonio, M.C., Benvenuto, A. (2016). Focus on pitavastatin. International Journal of Cardiology and Lipidology Research, 3, 11-19. doi: http://dx.doi.org/10.15379/2410-2822.2016.03.01.03
Carswell, C.I., Plosker, G.L., Jarvis, B. (2002). Rosuvastatin. Drugs, 62(14). 2075-2085. doi: https://doi.org/10.2165/00003495-200262140-00008.
Chen, M., Zhou, S.Y., Fabriaga, E., Zhang, P.H., Zhou, Q. (2018). Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review. Journal of Food and Drug Analysis, 26, S61-S71. doi: https://doi.org/10.1016/j.jfda.2018.01.009.
Costache, I.I., Miron, A., Hsncianu, M., Aursulesei, V., Dan Costache, A., Aprotosoaie, A.C. (2019). Pharmacokinetic interactions between cardiovascular medicines and plant products. Cardiovascular Therapeutics, 2019, 1-19. doi: https://doi.org/10.1155/2019/9402781.
Dahan, A., Altman, H. (2004). Food–drug interaction: grapefruit juice augments drug bioavailability mechanism, extent and relevance. European Journal of Clinical Nutrition, 58, 1-9. doi: 10.1038/sj.ejcn.1601736.
Dahan, A., Amidon, G.L. (2009). Grapefruit juice and its constituents augment colchicine intestinal absorption: Potential hazardous interaction and the role of P-glycoprotein. Pharmaceutical Research, 26(4), 883-892. doi: 10.1007/s11095-008-9789-7.
De Castro, W.V., Talcott, S.M., Rubner, A., Butterweck, V., Derendorf, H. (2006). Variation of flavonoids and furanocoumarins in grapefruit juices: A potential source of Variability in grapefruit Juice−Drug interaction studies. Journal of Agricultural and Food Chemistry, 54, 249-255. doi: https://doi.org/10.1021/jf0516944.
De Castro, W.V., Talcott, S.M., Derendorf, H., Butterweck, V. (2007). Grapefruit juice–drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 Cells. Journal of Pharmaceutical Sciences, 96(10), 2808-2817. doi: 10.1002/jps.20975.
Donovan, J.M., Kisicki, J.C., Stiles, M.R., Tracewell, W.G., Burke, S.K. (2002). Effect of colesevelam on lovastatin pharmacokinetics. The Annals of Pharmacotherapy, 36, 392-397. doi: https://doi.org/10.1345/aph.1A144.
Dresser, G.K., Bailey, D.G. (2003). The effects of fruit juices on drug disposition: a new model for drug interactions. European Journal of Clinical Investigation, 33(2), 10-16. doi: https://doi.org/10.1046/j.1365-2362.33.s2.2.x.
Duggan, S.T. (2012). Pitavastatin a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs, 72(4), 565-584. doi: https://doi.org/10.2165/11207180-000000000-00000.
Eagling, V.A., Profit, L., Back, D.J. (1999). Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. British Journal of Clinical Pharmacology, 48, 543-552. doi: 10.1046/j.1365-2125.1999.00052.x.
Fukazawa, I., Uchida, N., Uchida, E., Yasuhara, H. (2003). Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. British Journal of Clinical Pharmacology, 57(4), 448-455. doi: 10.1046/j.1365-2125.2003.02030.x.
Fukuda, K., Ohta, T., Oshima, Y., Ohashi, N., Yoshikawa, M., Yamazoe, Y. (1997). Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics, 7(5), 391-396. doi: 10.1097/00008571-199710000-00008.
Fukuda, K., Guo, L., Ohashi, N., Yoshikawa, M., Yamazoe, Y. (2000). Amounts and variation in grapefruit juice of the main components causing grapefruit–drug interaction. Journal of Chromatography B, 741, 195-203. doi: https://doi.org/10.1016/S0378-4347(00)00104-3.
Gazzerro, P., Proto, M.C., Gangemi, G., Malfitano, A.M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., Bifulco, M. (2012). Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacological Reviews, 64, 102-146. doi: http://dx.doi.org/10.1124/pr.111.004994.
Goff-Klein, N.L., Klein, L., Herin, M., Koffel, J.C., Ubeaud, G. (2004). Inhibition of in-vitro simvastatin metabolism in rat liver microsomes by bergamottin, a component of grapefruit juice. Journal of Pharmacy and Pharmacology, 56, 1007-1014. doi: 10.1211/0022357044012.
Golomb, B.A., Evans, M.A. (2008). Statin adverse effects a review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs, 8(6), 373-418. doi: https://doi.org/10.2165/0129784-200808060-00004.
Graeser, K.A., Strachan, C.J., Patterson, J.E., Gordon, K.C., Rades, T. (2008). Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin. Crystal Growth & Design, 8(1), 128-135. doi: https://doi.org/10.1021/cg700913m.
Greenblatt, D.J., Patki, K.C., von Moltke, L.L., Shader, R.I. (2001). Drug interactions with grapefruit juice: An update. Journal of Clinical Psychopharmacology, 21(4), 357-359.
Guo, L.Q., Yamazoe, Y. (2004). Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacologica Sinica, 25(2), 129-136.
Hanley, M.J., Cancalon, P., Widmer, W.W., Greenblatt, D.J. (2011). The effect of grapefruit juice on drug disposition. Expert Opinion on Drug Metabolism & Toxicology, 7(3), 267-286. doi: https://doi.org/10.1517/17425255.2011.553189.
Hatanaka, T. (2000). Clinical pharmacokinetics of pravastatin mechanisms of pharmacokinetic events. Clinical Pharmacokinetics, 39(6), 397-412. doi: https://doi.org/10.2165/00003088-200039060-00002.
Hayashi, T., Yokote, K., Saito, Y., Iguchi, A. (2007). Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opinion on Pharmacotherapy, 8(14), 2315-2327. doi: 10.1517/14656566.8.14.2315.
Ho, P.C., Saville, D.J. (2001). Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. Journal of Pharmacy and Pharmaceutical Sciences, 4(3), 217-227.
Ho, R.H., Tirona, R.G., Leake, B.F., Glaeser, H., Lee, W., Lemke, C.J., Wang, Y., Kim, R.B. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology, 130(6), 1793-1806. doi: https://doi.org/10.1053/j.gastro.2006.02.034.
Hu, M., Mak, V.W.L., Chu, T.T.W., Waye, M.M.Y., Tomlinson, B. (2009). Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Current Pharmacogenomics and Personalized Medicine, 7, 1-26. doi: https://doi.org/10.2174/187569209787582349.
Hu, M., Lun Mak, V.W., Yin, O.Q.P., Chu, T.T.W., Tomlinson, B. (2013). Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metabolism and Pharmacokinetics, 28(2), 104-108. doi: https://doi.org/10.2133/dmpk.DMPK-12-RG-067.
Hung, W.L., Suh, J.H., Wang, Y. (2017). Chemistry and health effects of furanocoumarins in grapefruit. Journal of Food and Drug Analysis, 25, 71-83. doi: http://dx.doi.org/10.1016/j.jfda.2016.11.008.
Igual, M., Martinez, E.G., Camacho, M.M., Navarrete, N.M. (2011). Changes in flavonoid content of grapefruit juice caused by thermal treatment and storage. Innovative Food Science and Emerging Techologies, 12, 153-162. doi: 10.1016/j.ifset.2010.12.010.
Kafle, A., Mohapatra, S.S., Sarma, J., Reddy, I. (2018). Food-drug interaction: A review. The Pharma Innovation Journal, 7(1), 114-118.
Kantola, T., Kivistö, K.T., Neuvonen, P.J. (1998). Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clinical Pharmacology & Therapeutics, 63(4), 397-402. doi: https://doi.org/10.1016/S0009-9236(98)90034-0.
Khan, F.N., Dehghan, M.H.G. (2011). Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. AAPS PharmSciTech, 12(4), 1077-1086. doi: https://doi.org/10.1208/s12249-011-9673-3.
Khan, S.I., Saha, S.K., Poddar, S.K., Bachar, R., Al Shoyaib, A., Chakrabarty, J.K., Promite, S., Bachar, S.C., Pal, T.K. (2017). Bioequivalence studies and pharmacokinetic properties of atorvastatin 40 mg tablet in healthy Bengali subjects. MOJ Bioequivalence & Bioavailability, 4(2), 1-7. doi: 10.15406/mojbb.2017.04.00064.
Kiani, J., Imam, S.Z. (2007). Medicinal importance of grapefruit juice and its interaction with various drugs. Nutrition Journal, 6(33), 1-9. doi: 10.1186/1475-2891-6-33.
Kim, J.S., Kim, M.S., Park, H.J., Jin, S.J., Lee, S., Hwang, S.J. (2008). Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. International Journal of Pharmaceutics, 359, 211-219. doi: 10.1016/j.ijpharm.2008.04.006.
Kong, R., Zhu, X., Meteleva, E.S., Chistyachenko, Y.S., Suntsova, L.P., Polyakov, N.E., Khvostov, M.V., Baev, D.S., Tolstikova, T.G., Yu, J., Dushkin, A.V., Su, W. (2017). Enhanced solubility and bioavailability of simvastatin by mechanochemically obtained complexes. International Journal of Pharmaceutics, 534, 108-118. doi: http://dx.doi.org/10.1016/j.ijpharm.2017.10.011.
Kumar, N., Chaurasia, S., Patel, R.R., Khan, G., Kumar, V., Mishra, B. (2017). Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile. Pharmaceutical Development and Technology, 22(2), 156-167. doi: 10.3109/10837450.2015.1108983.
Lada, M.K.,Baba, K., Dolatowski, F., Dobrowolska, A., Rakicka, M. (2018). The polymorphism of statins and its effect on their physicochemical properties. Polymers in Medicine, 48(2), 77-82. doi: 10.17219/pim/102978.
Langtry, H.D., Markham, A. (1999). Fluvastatin a review of its use in lipid disorders. Drugs, 57(4), 583-606.
Lee, J.W., Morris, J.K., Wald, N.J. (2016). Grapefruit juice and statins. The American Journal of Medicine, 129, 26-29. doi: http://dx.doi.org/10.1016/j.amjmed.2015.07.036.
Lennernas, H. (2003). Clinical pharmacokinetics of atorvastatin. Clinical Pharmacokinetics, 42(13), 1141-1160. doi: https://doi.org/10.2165/00003088-200342130-00005.
Lilja, J.J., Kivistö, K.T., Backman, J.T., Lamberg, T.S., Neuvonen, P.J. (1998). Grapefruit juice substantially increases plasma concentrations of buspirone. Clinical Pharmacology & Therapeutics, 64(6), 655-660. doi: https://doi.org/10.1016/S0009-9236(98)90056-X.
Lilja, J.J., Kivistö, K.T., Neuvonen, P.J. (1999). Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clinical Pharmacology & Therapeutics, 66(2), 118-127. doi: https://doi.org/10.1053/cp.1999.v66.100453001.
Lilja, J.J., Kivistö, K.T., Neuvonen, P.J. (2000). Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clinical Pharmacology & Therapeutics, 68(4), 384-390. doi: 10.1067/mcp.2000.110216.
Lilja, J.J., Neuvonen, M., Neuvonen, P.J. (2004). Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. British Journal of Clinical Pharmacology, 58(1), 56-60. doi: 10.1111/j.1365-2125.2004.02095.x.
Mauro, V.F. (1993). Clinical pharmacokinetics and practical applications of simvastatin. Clinical Pharmacokinetics, 24(3), 195-202. doi: https://doi.org/10.2165/00003088-199324030-00002.
McKenney, J. (2003). Pharmacologic characteristics of statins. Clinical Cardiology, 26, 32-38. doi: https://doi.org/10.1002/clc.4960261507.
Melough, M.M., Chun, O.K. (2018). Dietary furocoumarins and skin cancer: A review of current biological evidence. Food and Chemical Toxicology, 122, 163-171. doi: https://doi.org/10.1016/j.fct.2018.10.027.
Mouly, S., Linares, C.L., Sellier, P.O., Sene, D., Bergmann, J.F. (2017). Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort? Pharmacological Research, 118, 82-92. doi: http://dx.doi.org/10.1016/j.phrs.2016.09.038.
Murphy, C., Deplazes, E., Cranfield, C.G., Garcia, A. (2020). The role of structure and biophysical properties in the pleiotropic effects of statins. International Journal of Molecular Sciences, 2020, 21(8745), 1-29. doi: 10.3390/ijms21228745.
Neuvonen, P.J., Backman, J.T., Niemi, M. (2008). Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clinical Pharmacokinetics, 47(7), 463-474. doi: https://doi.org/10.2165/00003088-200847070-00003.
Ohta, T., Maruyama, T., Nagahashi, M., Miyamoto, Y., Hosoi, S., Kiuchi, F., Yamazoe, Y., Tsukamoto, S. (2002). Paradisin C: a new CYP3A4 inhibitor from grapefruit juice. Tetrahedron, 58, 6631-6635. doi: https://doi.org/10.1016/S0040-4020(02)00739-1.
Paine, M.F., Criss, A.B., Watkins, P.B. (2004). Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metabolism and Disposition, 32(10), 1146-1153. doi: https://doi.org/10.1124/dmd.104.000547.
Paine, M.F., Widmer, W.W., Hart, H.L., Pusek, S.N., Beavers, K.L., Criss, A.B., Brown, S.S., Thomas, B.F., Watkins, P.B. (2006). A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. The American Journal of Clinical Nutrition, 83, 1097-1105. doi: https://doi.org/10.1093/ajcn/83.5.1097.
Pirmohamed, M. (2013). Drug-grapefruit juice interactions: two mechanisms are clear but individual responses vary. British Medical Journal, 346, 1-3. doi: https://doi.org/10.1136/bmj.f1.
Plosker, G.L., Wagstaff, A.J. (1996). Fluvastatin a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs, 51(3), 433-459. doi: https://doi.org/10.2165/00003495-199651030-00011.
Quion, J.A.V., Jones, P.H. (1994). Clinical pharmacokinetics of pravastatin. Clinical Pharmacokinetics, 27(2), 94-103. doi: https://doi.org/10.2165/00003088-199427020-00002.
Rebello, S., Zhao, S., Hariry, S., Dahlke, M., Alexander, N., Vapurcuyan, A., Hanna, I., Jarugula, V. (2012). Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. European Journal of Clinical Pharmacology, 68, 697-708. doi: 10.1007/s00228-011-1167-4.
Reddy, P., Ellington, D., Zhu, Y., Zdrojewski, I., Parent, S.J., Harmatz, J.S., Derendorf, H., Greenblatt, D.J., Browne, K. (2011). Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. British Journal of Clinical Pharmacology, 72(3), 434-441. doi: 10.1111/j.1365-2125.2011.03996.x.
Rogers, J.D., Zhao, J., Liu, L., Amin, R.D., Gagliano, K.D., Porras, A.G., Blum, R.A., Wilson, M.F., Stepanavage, M., Vega, J.M. (1999). Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clinical Pharmacology & Therapeutics, 66(4), 358-366. doi: https://doi.org/10.1053/cp.1999.v66.a101208.
Ross, S.A., Ziska, D.S., Zhaod, K., ElSohly, M.A. (2000). Variance of common flavonoids by brand of grapefruit juice. Fitoterapia, 71, 154-161. doi: https://doi.org/10.1016/S0367-326X(99)00131-8.
Row, E.C., Brown, S.A., Stachulski, A.V., Lennard, M.S. (2006). Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CYP3A4. Organic and Biomolecular Chemistry, 4, 1604-1610. doi: 10.1039/b601096b.
Saito, Y. (2011). Pitavastatin: An overview. Atherosclerosis Supplements, 12(3), 271-276. doi: https://doi.org/10.1016/S1567-5688(11)70886-8.
Schachter, M. (2004). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology, 19, 117-125. doi: 10.1111/j.1472-8206.2004.00299.x.
Schmidt, L.E., Dalhoff, K. (2002). Food-drug interactions. Drugs, 62(10), 1481-1502. doi: https://doi.org/10.2165/00003495-200262100-00005.
Scott, L.J., Curran, M.P., Figgitt, D.P. (2004). Rosuvastatin a review of its use in the management of dyslipidemia. American Journal of Cardiovascular Drugs, 4(2), 117-138. doi: https://doi.org/10.2165/00129784-200404020-00005.
Scripture, C.D., Pieper, J.A. (2001). Clinical pharmacokinetics of fluvastatin. Clinical Pharmacokinetics, 40(4), 263-281. doi: https://doi.org/10.2165/00003088-200140040-00003.
Sharannavar, B.R., Gadad, A.P. (2018). Physicochemical characterization and dissolution study of spray dried amorphous lovastatin with polyvinylpyrrolidone K30. The Pharma Innovation Journal, 7(3), 498-502.
Shayanfar, A., Ghavimi, H., Hamishehkar, H., Jouyban, A. (2013). Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. The Journal of Pharmacy and Pharmaceutical Sciences, 16(4), 577-587. doi: https://doi.org/10.18433/J3XS4S.
Shirasaka, Y., Suzuki, K., Nakanishi, T., Tamai, I. (2010) Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharmaceutical Research, 27, 2141-2149. doi: 10.1007/s11095-010-0216-5.
Shirasaka, Y., Suzuki, K., Shichiri, M., Nakanishi, T., Tamai, I. (2010). Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and p-glycoprotein/multidrug resistance 1. Drug Metabolism and Pharmacokinetics, 26(2), 171-179. doi: 10.2133/dmpk.DMPK-10-RG-073.
Shirasaka, Y., Suzuki, K., Nakanishi, T., Tamai, I. (2011). Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or p-glycoprotein. Journal of Pharmaceutical Sciences, 100(9), 3843-3853. doi: 10.1002/jps.22586.
Shirasaka, Y., Shichiri, M., Mori, T., Nakanishi, T., Tamai, I. (2013). Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions. Journal of Pharmaceutical Sciences, 102(1), 280-288Sicari, V., Pellicano, T.M., Giuffre, A.M., Zappia, C., Capocasale, M., Poiana, M. (2018). Physical chemical properties and antioxidant capacities of grapefruit juice (citrus paradisi) extracted from two different varieties. International Food Research Journal, 25(5), 1978-1984. doi: https://doi.org/10.1002/jps.23357.
Sirtori, C.R. (2014). The pharmacology of statins. Pharmacological Research, 88(2014), 3-11. doi: http://dx.doi.org/10.1016/j.phrs.2014.03.002.
Spence, D.J., Dresser, G.K. (2016). Overcoming challenges with statin therapy. Journal of the American Heart Association, 5(1), 1-13. doi: 10.1161/JAHA.115.002497.
Srinivas, C., Sagar, S.V. (2012). Enhancing the bioavailability of simvastatin using microemulsion drug delivery system. Asian Journal of Pharmaceutical and Clinical Research, 5(4), 134-139.
Tassaneeyakul, W., Guo, L.Q., Fukuda, K., Ohta, T., Yamazoe, Y. (2000). Inhibition selectivity of grapefruit juice components on human cytochromes P450. Archives of Biochemistry and Biophysics, 378(2), 356-363. doi: https://doi.org/10.1006/abbi.2000.1835.
Vanamala, J., Reddivari, L., Yoo, K.S., Pike, L.M., Patil, B.S. (2006). Variation in the content of bioactive flavonoids in different brands of orange and grapefruit juices. Journal of Food Composition and Analysis, 19, 157-166. doi: 10.1016/j.jfca.2005.06.002.
Varma, M.V., Gardner, I., Steyn, S.J., Nkansah, P., Rotter, C.J., Pickett, C.W., Zhang, H., Di, L., Cram, M, Fenner, K.S., El-Kattan, A.F. (2012). pH-dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Molecular Pharmaceutics, 9, 1199-1212. doi: dx.doi.org/10.1021/mp2004912.
Veronese, M.L., Gillen, L.P., Burke, J.P., Dorval, E.P., Hauck, W.W.,Pequignot, E., Waldman, S.A., Greenberg, H.E. (2003). Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. The Journal of Clinical Pharmacology, 43, 831-839. doi: 10.1177/0091270003256059.
White, C.M. (2002). A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. The Journal of Clinical Pharmacology, 42, 963-970. doi: https://doi.org/10.1177/009127000204200902.
Williams, D., Feely, J. (2002). Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Pharmacokinetics, 41(5), 343-370. doi: https://doi.org/10.2165/00003088-200241050-00003.
Zhang, J. (2007). Flavonoids in grapefruit and commercial grapefruit juices: concentration, distribution, and potential health benefits. Proceedings of the Florida State Horticultural Society, 120, 288-294.
Zolkiflee, N.F., Affandi, M.M., Majeed, A.B.A. (2017). Lovastatin: history, physicochemistry, pharmacokinetics and enhanced solubility. International Journal of Research in Pharmaceutical Sciences, 8(1), 90-102.